Temporal relationships among uterine pituitary adenylate cyclase-activating polypeptide, decidual prolactin-related protein and progesterone receptor mRNAs expressions during decidualization and gestation in rats.
Pituitary adenylate cyclase-activating peptide (PACAP), a novel compound with vasoactive intestinal polypeptide-like activity, was recently shown to be localized in the neuronal endings of the human uterus. The purpose of the present study was to assess the functional presence of PACAP mRNA in the decidual endometrium and its relationship to the expression levels of decidual prolactin-related protein (dPRP) and the progesterone receptor mRNAs during decidualization and pregnancy in Sprague-Dawley rats. PACAP was constitutively and temporally expressed in the decidual endometrium and gravid uterus. The time-dependent correlated expression levels of PACAP, dPRP and the progesterone receptor were induced by the neurogenic reproductive signals, i.e. the vagino-cervical/deciduogenic stimuli of decidualization and by the normal equivalent stimuli of mating/blastocyst implantation of gestation. Correlation among the mRNA expression levels of PACAP, dPRP and the progesterone receptor and the coordinated inhibitory actions of the anti-progesterone (RU-486) suggest that there is also correlated time-dependent steroid regulation of the mRNA levels of PACAP, dPRP and the progesterone receptor in the decidual and pregnant uteri. One possible functional meaning for the time-related localization of endometrial/uterine PACAP could be to facilitate endometrial blood flow and increase the availability of metabolic substrates to the developing deciduoma or embryo. The study demonstrates the potential importance of PACAP expression in the regulation of the maternal feto-placental component and suggests a prominent reproductive role for the neuropeptide in mammalian pregnancy.
Spencer
F
F
Health Research Center, Southern University, 70813, Baton Rouge, LA, USA. fitz@grant.phys.subr.edu
Chi
L
L
Zhu
M
M
D000818:Animals; D017931:DNA Primers; D003656:Decidua / Q000378:metabolism; D004717:Endometrium / Q000378:metabolism; D005260:Female; D006023:Glycoproteins / Q000378:metabolism; D006727:Hormone Antagonists / Q000494:pharmacology; D008297:Male; D015735:Mifepristone / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000235:genetics* / Q000378:metabolism; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000378:metabolism; D045384:Pregnancy-Associated alpha 2-Macroglobulins; D011388:Prolactin / Q000031:analogs & derivatives / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011980:Receptors, Progesterone / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction; D014599:Uterus / Q000378:metabolism
D017931:DNA Primers; D006023:Glycoproteins; D006727:Hormone Antagonists; D018377:Neurotransmitter Agents; D011257:Pregnancy Proteins; D045384:Pregnancy-Associated alpha 2-Macroglobulins; C079559:Prl8a2 protein, rat; D012333:RNA, Messenger; D011980:Receptors, Progesterone; C020881:decidualization-associated protein, rat; D015735:Mifepristone; D011388:Prolactin